摘要
目的:探讨中药骨康对非骨水泥型人工假体周围早期骨量的影响。方法:50例患者随机分为对照组和治疗组,术后1周对照组予以口服钙尔奇D片,治疗组予以骨康1剂/日+钙尔奇D片。连续服用3周,休息2周,5周为1疗程,连续5个疗程。分别于术后7天、3个月、6个月行假体周围骨密度(DEXA)检测。结果:50例病例中,43例获得完整随访。术后3个月、6个月假体周围骨量(ROI1区和ROI7区)对照组与治疗组相比有显著性差异(P<0.01)。结论:中药骨康能减少假体周围早期骨量丢失。
Objective：To explore the early effect of Gukang on the cementless periprosthetic bone density. Methods： fifty patients who had undergone hip arthroplasty were randomized into control group and the Gukang group. After 1 week postop eratively, the patients of the control group received cyclic therapy with caltrate D（ 1 tablet/time, 1 time/day）. The patients in the Gukang group received cyclic therapy with Gukang（ldose/day） plus caltrate D（1 tablet/time, 1 time/day）. The cyclic therapy was intermittent administration. Namely, the medicine was given in a 3-week cycle followed by 2 weeks of rest and repeated every 5 weeks. Periprosthetic bone mineral density（BMD） was measured by dual energy X--ray absorptiometry（DEXA） at 1 week, 3 months, and 6 months respectively. Results：43 of 50 patients have completed 6 months＇ followup. The mean periprosthetic BMD change was significantly different in the ROI1 and ROI7 between the two groups（P〈0. 01 Gukang group vs. control group）. Conclusion：Alendronate can reduce early periprosthetic bone loss .
出处
《中国中医骨伤科杂志》
CAS
2006年第5期6-8,共3页
Chinese Journal of Traditional Medical Traumatology & Orthopedics
